Russell Investments Group Ltd. Has $280,000 Holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Russell Investments Group Ltd. trimmed its position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 66.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 41,286 shares of the biopharmaceutical company’s stock after selling 81,734 shares during the quarter. Russell Investments Group Ltd. owned 0.07% of Vanda Pharmaceuticals worth $280,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in VNDA. JPMorgan Chase & Co. increased its stake in Vanda Pharmaceuticals by 4.8% in the first quarter. JPMorgan Chase & Co. now owns 363,768 shares of the biopharmaceutical company’s stock valued at $4,114,000 after acquiring an additional 16,716 shares during the last quarter. MetLife Investment Management LLC boosted its stake in Vanda Pharmaceuticals by 56.0% in the first quarter. MetLife Investment Management LLC now owns 30,601 shares of the biopharmaceutical company’s stock valued at $346,000 after buying an additional 10,989 shares in the last quarter. Panagora Asset Management Inc. boosted its stake in Vanda Pharmaceuticals by 26.1% in the first quarter. Panagora Asset Management Inc. now owns 46,531 shares of the biopharmaceutical company’s stock valued at $526,000 after buying an additional 9,642 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in Vanda Pharmaceuticals by 14.1% in the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 48,029 shares of the biopharmaceutical company’s stock valued at $543,000 after buying an additional 5,922 shares in the last quarter. Finally, Yousif Capital Management LLC lifted its stake in Vanda Pharmaceuticals by 2.4% in the 1st quarter. Yousif Capital Management LLC now owns 50,710 shares of the biopharmaceutical company’s stock valued at $574,000 after purchasing an additional 1,180 shares during the last quarter. 97.92% of the stock is owned by institutional investors.

Vanda Pharmaceuticals Stock Down 1.5 %

Shares of VNDA opened at $5.11 on Tuesday. Vanda Pharmaceuticals Inc. has a 12-month low of $5.11 and a 12-month high of $11.04. The business has a 50-day simple moving average of $6.03 and a two-hundred day simple moving average of $6.31. The stock has a market cap of $293.88 million, a PE ratio of 18.93 and a beta of 0.70.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.16. Vanda Pharmaceuticals had a net margin of 6.25% and a return on equity of 2.81%. The firm had revenue of $46.06 million for the quarter, compared to analyst estimates of $49.00 million.

Insiders Place Their Bets

In other Vanda Pharmaceuticals news, Director Stephen Ray Mitchell sold 6,500 shares of Vanda Pharmaceuticals stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $6.05, for a total transaction of $39,325.00. Following the transaction, the director now directly owns 29,328 shares of the company’s stock, valued at approximately $177,434.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Vanda Pharmaceuticals news, Director Stephen Ray Mitchell sold 6,500 shares of the firm’s stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $6.05, for a total transaction of $39,325.00. Following the completion of the transaction, the director now owns 29,328 shares in the company, valued at approximately $177,434.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Timothy Williams sold 14,600 shares of the firm’s stock in a transaction that occurred on Tuesday, June 13th. The stock was sold at an average price of $6.56, for a total transaction of $95,776.00. Following the transaction, the senior vice president now owns 88,913 shares of the company’s stock, valued at approximately $583,269.28. The disclosure for this sale can be found here. Insiders have sold 43,036 shares of company stock valued at $271,425 in the last ninety days. 7.70% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Separately, StockNews.com initiated coverage on shares of Vanda Pharmaceuticals in a research note on Thursday, August 17th. They issued a “buy” rating for the company.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.